A full list of all of the tablets included in the Aurobindo Pharma recall can be found here.
It said Mylan Pharmaceuticals "is expanding its voluntary recall to include all lots of non-expired valsartan-containing products due to trace amounts of N-Nitrosodiethylamine (NDEA) in the valsartan active pharmaceutical ingredient (API) manufactured by" by Mylan Inc.
Losartan can also be perscribed to treat hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients.
To date, Aurobindo Pharma says it has not received any reports of adverse events related to the recall.
Patients who are on Losartan should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.
A list of losartan medications under recall can be accessed via the FDA's website (pdf).
While the drug impurities are serious enough to warrant these callbacks, halting the use of a blood pressure medication can cause other serious medical issues. Products can be identified by checking the product name, manufacturer details, and batch or lot number on the pill bottles. They recommend that patients consult with their doctor or friendly neighborhood pharmacist to discuss their options for treatment alternatives.